Compare TNC & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNC | MNMD |
|---|---|---|
| Founded | 1870 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Pharmaceuticals and Biotechnology |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | N/A | N/A |
| Metric | TNC | MNMD |
|---|---|---|
| Price | $73.91 | $13.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $102.00 | $30.33 |
| AVG Volume (30 Days) | 140.5K | ★ 2.0M |
| Earning Date | 02-17-2026 | 11-06-2025 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.91 | N/A |
| Revenue | ★ $1,240,800,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.63 | N/A |
| P/E Ratio | $25.33 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $67.32 | $4.70 |
| 52 Week High | $90.44 | $14.43 |
| Indicator | TNC | MNMD |
|---|---|---|
| Relative Strength Index (RSI) | 44.08 | 57.40 |
| Support Level | $74.67 | $12.85 |
| Resistance Level | $75.87 | $13.54 |
| Average True Range (ATR) | 1.47 | 0.69 |
| MACD | -0.12 | 0.05 |
| Stochastic Oscillator | 15.25 | 62.94 |
Tennant Co is a manufacturer of floor cleaning equipment, wood flooring, and wood products. It operates in four geographic business units including North America; Latin America; Europe, Middle East, Africa; and Asia Pacific. The company offers products and solutions consisting of mechanized cleaning equipment, detergent-free, and other sustainable cleaning technologies, aftermarket parts and consumables, equipment maintenance and repair service, specialty surface coatings, and business solutions such as financing, rental and leasing programs, and machine-to-machine asset management solutions.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).